Veru Inc.

NasdaqCM:VERU 주식 보고서

시가총액: US$114.2m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Veru 관리

관리 기준 확인 3/4

Veru's CEO는 Mitch Steiner, Oct2016 에 임명되었습니다 의 임기는 7.67 년입니다. 총 연간 보상은 $ 4.71M, 18.4% 로 구성됩니다. 18.4% 급여 및 81.6% 보너스(회사 주식 및 옵션 포함). 는 $ 5.69M 가치에 해당하는 회사 주식의 4.84% 직접 소유합니다. 5.69M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 3.5 년입니다.

주요 정보

Mitch Steiner

최고 경영자

US$4.7m

총 보상

CEO 급여 비율18.4%
CEO 임기7.7yrs
CEO 소유권4.8%
경영진 평균 재임 기간5.8yrs
이사회 평균 재임 기간3.5yrs

최근 관리 업데이트

Recent updates

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

May 31
Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09
The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16
Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17
Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14
Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Jan 13
Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Nov 13
Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Oct 17

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Sep 26
Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed

Sep 19

Veru: A Good Combination Of A Stable Business And Growth Opportunities

Sep 13

Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy

Sep 07

Veru sheds 13% to end rally as director sells shares

Aug 18

Veru Q3 2022 Earnings Preview

Aug 10

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Aug 03

Veru eligible for expedited review in U.K. for COVID-19 therapy

Jul 25

Veru: The Signs Seem To Point To An EUA For Sabizabulin

Jul 13

Veru phase 3 results of sabizabulin for COVID-19 published in NEJM

Jul 06

Veru: On Right Track For FDA EUA Submission

May 27

Is Veru (NASDAQ:VERU) Using Debt Sensibly?

May 25
Is Veru (NASDAQ:VERU) Using Debt Sensibly?

CEO 보상 분석

Mitch Steiner 의 보수는 Veru 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$39m

Dec 31 2023n/an/a

-US$63m

Sep 30 2023US$5mUS$866k

-US$93m

Jun 30 2023n/an/a

-US$120m

Mar 31 2023n/an/a

-US$136m

Dec 31 2022n/an/a

-US$116m

Sep 30 2022US$6mUS$761k

-US$84m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021n/an/a

-US$16m

Sep 30 2021US$2mUS$618k

US$7m

Jun 30 2021n/an/a

-US$144k

Mar 31 2021n/an/a

-US$476k

Dec 31 2020n/an/a

US$2m

Sep 30 2020US$1mUS$502k

-US$19m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019n/an/a

-US$13m

Sep 30 2019US$800kUS$392k

-US$12m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$22m

Dec 31 2018n/an/a

-US$22m

Sep 30 2018US$740kUS$383k

-US$24m

Jun 30 2018n/an/a

-US$21m

Mar 31 2018n/an/a

-US$14m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017US$831kUS$406k

-US$9m

보상 대 시장: Mitch 의 총 보상 ($USD 4.71M )은 US 시장( $USD 683.56K ).

보상과 수익: Mitch 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mitch Steiner (63 yo)

7.7yrs

테뉴어

US$4,714,041

보상

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...

리더십 팀

이름위치테뉴어보상소유권
Mitchell Steiner
Chairman7.7yrsUS$4.71m4.84%
$ 5.5m
Harry Fisch
Vice Chairman & Chief Corporate Officer7.7yrs데이터 없음5.47%
$ 6.3m
Michele Greco
CFO & Chief Administrative Officer6.5yrsUS$1.55m0.066%
$ 75.0k
K. Barnette
Chief Scientific Officer5.8yrsUS$1.69m0.0034%
$ 3.9k
Samuel Fisch
Executive Director of Investor Relations & Corporate Communications5.2yrs데이터 없음데이터 없음
Michael Purvis
Executive VP3.3yrs데이터 없음데이터 없음
Kevin Gilbert
Executive Vice President of Corporate Development7.4yrs데이터 없음데이터 없음
Martin Tayler
Executive Vice President of FC2 Global Operationsno dataUS$193.01k데이터 없음
Philip Greenberg
Executive VP & Deputy General Counsel3.4yrs데이터 없음데이터 없음
Domingo Rodriguez
Executive Vice President of Global Clinical Operations6.2yrs데이터 없음데이터 없음
Gary Bird
Executive Vice President of Quality & Regulatory Affairs5.3yrs데이터 없음데이터 없음
Jason Davies
Executive VP and GM of UK1.8yrs데이터 없음데이터 없음

5.8yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 관리: VERU 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Mitchell Steiner
Chairman7.7yrsUS$4.71m4.84%
$ 5.5m
Harry Fisch
Vice Chairman & Chief Corporate Officer7.7yrs데이터 없음5.47%
$ 6.3m
Louis Aronne
Chief Medical Advisor & Member of the Scientific Advisoryless than a year데이터 없음데이터 없음
David D. Ho
Chairman of Scientific Advisory Board1.4yrs데이터 없음데이터 없음
Andrew Love
Board Observer7.7yrs데이터 없음데이터 없음
Robert Schooley
Member of the Scientific Advisory Boardless than a year데이터 없음데이터 없음
Michael Rankowitz
Independent Director6.3yrsUS$875.93k0.068%
$ 78.0k
Xiaoqin Lu
Independent Director3.1yrsUS$835.75k0.0067%
$ 7.6k
Caroline Apovian
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Mario Eisenberger
Independent Director7.7yrsUS$795.57k0%
$ 0
Grace Hyun
Independent Director3.8yrsUS$755.39k0.010%
$ 11.5k
Erik Swenson
Member of the Scientific Advisory Boardless than a year데이터 없음데이터 없음

3.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: VERU 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.